Levothyroxine Shows No Benefit in Older Adults
A new systematic review in BMC Geriatrics finds that levothyroxine offers no measurable benefit for older adults with subclinical hypothyroidism. Patient‑reported quality‑of‑life, cognitive function, physical performance, and major cardiovascular events were unchanged compared with observation or placebo. The analysis also highlights overtreatment risks such as atrial fibrillation and bone loss. These results are likely to trigger revisions of clinical guidelines toward more conservative, individualized management.
BillionToOne Shares Tumble 3.7% After Appointing New Oncology Chief
BillionToOne, Inc. saw its Nasdaq‑listed shares drop 3.66% to $79.92 following the announcement that Allen Chen will lead medical affairs and clinical development for oncology. The move comes as the company expands its Northstar liquid‑biopsy platform, and investors are weighing...
Cell‑Free DNA Production Ends Decades‑Old Cloning Bottleneck
Most of synthetic biology has been completely transformed in the last decade. DNA manufacturing? Still running on cloning workflows from the 1970s. That's the bottleneck Jodi Barrientos, CEO of @ribbonbiolabs, is tackling head-on — and she's on the @SynBioBeta Main Stage on...
Mono Infection Triples Risk of Developing Multiple Sclerosis
New study has strengthened link between infectious mono and Multiple Sclerosis. By analyzing 2 decades of health records, researchers found people who contracted mono as teenagers or adults were 3x more likely to develop MS later vs those who didn’t https://t.co/6DLZMEWyU6
Parents Spend $50k on Overseas Stem Cell Therapy as Experts Issue Warning
Australian parents spent roughly US$33,000 on a stem‑cell procedure in Thailand for their five‑year‑old son with septo‑optic dysplasia, a rare eye condition affecting only 54 Australians. After multiple treatments, the child’s visual acuity improved from 1/60 to 3/60, allowing limited...
H5N1 Bird‑to‑Cattle Spillover Traced Across US
So pleased to contribute to this preprint on H5N1 spillover from birds to dairy cattle from the Moo Flu Crew, led by the excellent @jepekar. We traced both B3.13 in Texas and D1.1 in Nevada and Arizona to look at...
All G Secures FDA Clearance for Cow‑Free Lactoferrin, Paving Way for Fermented Alt‑Dairy
All G, a Sydney‑based precision‑fermentation company, earned a U.S. FDA no‑questions letter for its cow‑free lactoferrin protein, clearing the path for commercial launch in the United States within months. The approval validates the ingredient’s safety and opens a new supply...
Study Links Black Women’s Lower IVF Success to Implantation Barriers
Researchers at the University of Pennsylvania analyzed over 246,000 IVF cycles and found Black women have a 45% live‑birth rate, far below the 60% seen for white women. The study suggests the disparity stems from implantation hurdles rather than ovarian...
Machine Learning-Based Prediction of SARS-CoV-2 Bioactivity: Integrating IC50 Regression and Activity Classification Using Multi-Task Neural Networks
Researchers introduced an integrated machine‑learning framework to predict SARS‑CoV‑2 compound potency. The system combines an IC50 regression model, a binary activity classifier, and a multi‑task neural network that performs both tasks simultaneously. Incorporating ligand efficiency as a classification criterion, the...
Mitochondrial Therapies Surge After First FDA Approval of Forzinity
Stealth BioTherapeutics secured the FDA's accelerated approval for elamipretide, branded Forzinity, the first drug that directly targets mitochondria. The milestone is igniting a broader push among biotech firms and academic teams to develop mitochondrial‑focused treatments for age‑related diseases.
Anthropic Pays $400M for AI Biotech, Touts 38,500% IRR
Anthropic acquired an AI for biological research startup for just over $400 million. You can read the letter Dimension wrote to their LPs which boasts a 38,513% IRR https://t.co/wneesuT5u7
Anthropic Buys Stealth Dimension-Backed Coefficient Bio in $400M+ Stock Deal
Anthropic has acquired stealth biotech startup Coefficient Bio in a stock transaction valued at just over $400 million. Coefficient Bio, founded eight months ago, develops AI models aimed at accelerating biological research and pursuing artificial superintelligence for science. The deal brings...
Science Spotlight: Three Teams Converge on RNU2‑2 as Targetable for Neurodevelopmental Epilepsies
Three independent research teams reported in Nature Genetics that variants in the non‑coding RNA RNU2‑2 cause both a dominant neurodevelopmental epilepsy syndrome and a prevalent recessive childhood disorder with epilepsy. By analyzing overlapping international cohorts and shared genomic datasets, they...
Shreehas Tambe Becomes First CEO of Newly Combined Biocon
Shreehas Tambe has been appointed the first chief executive officer of the newly combined Biocon entity, formed after Biocon’s merger with contract‑research firm Syngene. The merged company is valued at roughly $5.5 billion and aims to become India’s largest biotech services...
Sunshine Biopharma Inc (SBFM) Q4 2025 Earnings Call Transcript
Sunshine Biopharma reported a $713 million cash balance and zero debt at year‑end, while GAAP operating expenses fell to $225 million, driven by lower stock‑based compensation. The company’s Biologics License Application for ivonesumab in EGFR‑mutant NSCLC was accepted by the FDA, with...
Hydrogel-Based Axon Model Improves Early Testing for MS Remyelination Therapies
University College London researchers have created a hydrogel‑based axon model that mimics the ~5 kPa softness and three‑dimensional geometry of real brain axons. The tunable micropillar arrays enable human oligodendrocytes to form compact, multilayered myelin, a first for fully hydrogel systems....
Vedanta Biosciences Announces the Phase 3 RESTORATiVE303 Study of VE303 for the Prevention of Recurrent C. Difficile Infection Will Continue...
Vedanta Biosciences announced that the independent Data Monitoring Committee has completed the first prespecified interim analysis of its Phase 3 RESTORATiVE303 trial and recommended the study continue unchanged. The interim data showed efficacy surpassing the futility threshold with no new safety...
JBS, the World’s Largest Meat Company, Opens $37M ‘Superprotein’ Centre in Brazil
JBS has opened a $37 million, 4,000‑square‑meter biotech centre in Florianópolis, Brazil, branded JBS Biotech, to develop "superproteins" – microbial, cultivated and plant‑based functional proteins for supplements and precision nutrition. The facility houses 20 specialised labs that span the entire research‑to‑production...
Platform for Precise Cellular Control Uses Non-Genetic DNA Decoupled From Genetic Information
Researchers at POSTECH have engineered a bacterial retron system to produce programmable, non‑genetic DNA inside living cells, allowing the DNA to act as a functional field agent rather than a static blueprint. The synthetic DNA fragments bind specific proteins, enabling...
Engineered E. Coli Dependency May Help Contain Microbes to Defined Areas
Researchers at the University of Delaware engineered two E. coli strains to create a self‑contained microbial partnership. One strain synthesizes a non‑standard amino acid, while the other depends on that amino acid for growth and protein production. When co‑cultured, the...
Biotech Innovation Makes Inroads Against Bleeding Disorders
Biotech breakthroughs have transformed bleeding disorders from fatal diagnoses into manageable chronic conditions, with extended‑half‑life clotting factors, subcutaneous non‑factor drugs, and emerging gene therapies extending dosing intervals to weeks or months. The National Bleeding Disorders Foundation’s Pathway to Cures fund...
Boston University to Apply Machine Learning to Alzheimer’s Biomarker and Cognitive Data
Boston University, leading the AI for Alzheimer’s Disease (AI4AD) consortium, is coordinating 11 research institutes to apply machine learning to massive genomic, biomarker and cognitive datasets. The team is building the PreSiBO database, which tags predictor, signature, biomarker and outcome...
Pharmaceutical Giant Pfizer Forced To Shut Down Updated COVID Vaccine Trials
Pfizer announced it is halting development of its updated COVID‑19 vaccine candidates, ending ongoing Phase 2/3 trials that targeted newer variants. The decision follows mixed efficacy data and waning commercial demand as the pandemic recedes. Pfizer will redirect resources toward...
FDA Clears Eli Lilly’s Once‑Daily GLP‑1 Pill Foundayo, Expanding Oral Obesity Options
The U.S. Food and Drug Administration approved Eli Lilly’s oral GLP‑1 obesity medication Foundayo on April 1, 2026. The once‑daily pill can be taken any time of day without food or water restrictions and is priced between $149 and $349 a month,...
Lipocine Shares Plunge 78% After Phase 3 Oral Brexanolone Trial Misses Primary Endpoint
Lipocine Inc.'s stock fell 78% to $2.00 after its Phase 3 placebo‑controlled trial of oral brexanolone (LPCN 1154) missed the primary efficacy endpoint for postpartum depression. The company said it will preserve capital and engage stakeholders to evaluate next steps, underscoring...
Sirolimus DCB in Peripheral Disease Makes Strides in Hard Outcomes: SirPAD
The SirPAD trial showed that a sirolimus‑coated drug‑coated balloon (MagicTouch) significantly lowered major adverse limb events (MALE) to 8.8% versus 15% with uncoated balloons in femoropopliteal and below‑the‑knee peripheral artery disease patients. At one year, the composite of unplanned amputation...
Blocking KDM4 Reactivates Tumor Suppressor, Halts AML
Scientists have restored a silenced tumor-suppressor gene in mice with acute myeloid leukemia by blocking KDM4 enzymes, suggesting a potential new therapeutic approach that avoids harming normal blood cells. leukemia
Nanosecond Electric Pulses Rejuvenate Aging Endothelial Cells
Nanosecond pulsed electric field applications rejuvenate aging endothelial cells by rescuing mitochondrial-to-nuclear retrograde communication https://t.co/DT8GXNLlxO
Combining Novel Dual HIF Inhibitors with Immunotherapy Erases Multiple Tumor Types in Mice
Researchers at Johns Hopkins and the University of Maryland have created first‑in‑class small‑molecule inhibitors that simultaneously block hypoxia‑inducible factors 1 and 2. In mouse models, the dual HIF‑1/2 inhibitors eradicated breast, colorectal, melanoma and prostate tumors when paired with checkpoint antibodies such...
FDA's Future: New CBER Chief & Rare Disease Flexibility
On this week’s pod, we chatted with @docrodwong about the FDA, the next CBER chief and regulatory flexibility for rare diseases https://t.co/f6L7gwcNsr via @statnews
Ancient Ig-Like Domain Controls Disease-Linked SWI/SNF Complexes
a (presumably primordial) Ig-like domain regulates the disease relevant SWI/SNF chromatin remodeling complexes that's pretty cool https://t.co/Iit0Swrx0I
Part 1—Jason Aldred, MD: Understanding Possible Side Effects When Treating Patients with Parkinson’s Disease
Dr. Jason Aldred of Selkirk Neurology highlights the safety profile of Vyalev (foscarbidopa/foslevodopa), a subcutaneous therapy for Parkinson's disease. He notes that injection‑site reactions such as erythema, swelling, tenderness, bruising, and induration are the most common adverse events. Aldred advises...
Plug-and-Play Sensor Listens to the Developing Brain
Researchers at North Carolina State University introduced CAMEO, a low‑cost, plug‑and‑play carbon‑nanotube sensor array for human cerebral organoids. The basket‑shaped device houses 12 flexible electrodes, delivering electrophysiological recordings comparable to high‑end systems while costing a fraction of traditional microelectrode arrays....
Cell Line Development Has to Evolve
Cell line development (CLD) remains a hidden bottleneck that dictates speed to clinic, manufacturability, and long‑term product performance. Traditional random‑integration and lengthy clone screening are giving way to engineered platforms, especially glutamine synthetase (GS) knockout systems, which reduce heterogeneity and...
Seeking Alternative Tools for Genetic Code Sequence Search
Anyone know of software or a web server that can search a sequence for alternative genetic codes? Been trying to install Codetta https://t.co/Wd7IMD23Cy but can't get it running so looking for alternatives.
Lowering Barriers Unlocks Biotech’s Biggest Potential
What if the biggest unlock in biotech is simply access? Douglas Crawford built MBC BioLabs to lower barriers and enable 500+ startups. Excited to have him at SynBioBeta 2026. Visit the @SynBioBeta website to read the full article. https://t.co/HEfhvmwZ8i
The Peptide Fad Lures Health Tech
Health‑tech firms are pivoting toward peptide therapeutics as the next growth engine after the blockbuster GLP‑1 weight‑loss drugs. Peptides, which include insulin and GLP‑1, are being explored for obesity, metabolic and chronic disease treatments. Industry analysts project the global peptide...
Exploring Structural Variation in Genomic Studies
Broad Institute’s Primer on Medical and Population Genetics released a new session exploring structural variation in genomic studies. The free weekly video series provides in‑depth introductions to complex trait genetics, covering topics from DNA sequencing to statistical analysis. Targeted at...
Two Neutral IVUS Trials in Complex PCI—And One Positive—Spark Debate
Three recent randomized trials compared intravascular ultrasound (IVUS) with angiography for guiding complex percutaneous coronary interventions (PCI). Only DKCRUSH VIII, which focused on true bifurcation lesions, demonstrated a 60% relative reduction in 1‑year target‑vessel failure. The European OPTIMAL and IVUS‑CHIP studies,...
Weizmann Scientists Engineer Tobacco Plant to Produce Five Psychedelics at Once
A team from the Weizmann Institute of Science has genetically modified a tobacco plant to produce five distinct psychedelic compounds in a single host. The breakthrough could streamline drug research and reduce ecological pressure on natural sources, while raising biosecurity...
GENFIT Reports Full-Year 2025 Financial Results and Provides Corporate Update
GENFIT reported 2025 results with cash €101.1 million (~$109 million) and revenue €65.4 million (~$70.6 million), the bulk coming from Ipsen milestones and royalties. Iqirvo® generated $208 million in full‑year sales, triggering a $20 million commercial milestone and activating an additional €30 million (~$32 million) royalty‑financing tranche. The...
Cocrystal Pharma Shares Jump 51% After FDA Grants Fast Track to Norovirus Drug
Cocrystal Pharma (COCP) saw its shares climb 50.98% to $1.54 after the FDA granted Fast Track designation to its oral antiviral candidate CDI-988 for norovirus. The designation could accelerate development and bring the first oral therapy for the virus closer...
UK and US Lock in Pharmaceutical Deal
The United Kingdom and the United States have finalized the legal text of a landmark pharmaceutical partnership that eliminates import tariffs on U.S. medicines and certain medical technologies for at least three years. The agreement arrives amid heightened diplomatic tension,...
TRPM3: The Ion Channel Behind Pain, Migraines, and ME/CFS
TRPM3 is a calcium‑permeable ion channel activated by heat and neurosteroids such as pregnenolone sulfate, playing a central role in pain perception, insulin secretion, and vascular regulation. Genetic variants in the TRPM3 gene have been associated with heightened susceptibility to...
Aspect Biosystems – Announces $280 Million Partnership with Government of Canada to Advance Development of Bioengineered Cellular Medicines
Aspect Biosystems secured a CAD $79 million (≈ $58 million USD) investment from the Government of Canada, funding a CAD $280 million (≈ $204 million USD) multi‑year project to accelerate its bioengineered cellular medicines pipeline. The funding builds on a prior CAD $200 million (≈ $146 million USD) co‑investment announced in 2024 and will expand...
Alpha Cognition Q4 2025 Earnings Show 62% Sales Surge as COO D’Angelo Drives Rollout
Alpha Cognition reported $2.8 million in Q4 2025 revenue, with ZUNVEYL sales up 62% quarter‑over‑quarter. COO Lauren D’Angelo highlighted a rapid go‑to‑market expansion across long‑term‑care facilities, while the company balances rising operating costs against a $66 million cash cushion.
Omics Consortium Established to Supercharge Climate-Adapted Wheat Breeding
The University of Adelaide is spearheading the Wheat Spatial Omics Consortium (WSOC), a partnership of more than 30 institutions in nine countries, to build a comprehensive spatial omics atlas of wheat. By mapping genes, proteins and metabolites at subcellular resolution,...
Feds Invest $79 Million in Aspect Biosystems to Develop 3D-Printed Tissue Treatment
Vancouver‑based Aspect Biosystems secured $79 million CAD (≈$58 million USD) from Canada’s Strategic Response Fund for a $280 million CAD (≈$204 million USD) project to scale its 3D‑printed tissue platform. The company will fund the remaining $201 million CAD (≈$147 million USD) and aims to enhance...
Biodexa Pharma Shares Surge 69% After Partnering with Syngene to Produce MTX240
Biodexa Pharmaceuticals saw its Nasdaq‑listed shares climb 69% after revealing a partnership with Syngene International to manufacture the active pharmaceutical ingredient and dosage form of its MTX240 candidate. The deal paves the way for an IND filing and a Phase...
Software Package Makes Gene Regulation Easier to Study—And Tweak
Researchers at VIB and KU Leuven introduced CREsted, a new software package for modeling and designing gene regulatory enhancers. The framework unifies preprocessing, deep‑learning model training, interpretation, and synthetic enhancer generation into a single, reusable workflow. Demonstrated on mouse brain,...